Still No Heart Risks With Lantus in ORIGINALE

VIENNA (MedPage Today) -- Insulin glargine (Lantus) continued to carry no increased risk of cardiovascular events compared with standard care in an extension of the ORIGIN trial, researchers reported here.
Source: MedPage Today Public Health - Category: American Health Source Type: news